Skip to Main Content

Paper Details

IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
JCI Insight
23
2021
C, C-peptide, CD4, CD4 memory subsets, CD4+, CD4+ T cell, CD4+ T cell phenotypes, CTSA, DC subset, Diabetes and Digestive and Kidney Diseases, IL-6 receptor, IL-6R, NCATS, Participants, T cell, T cell populations, T cells, T effector cell, Th17 cells, Tocilizumab, Treg, Tregs, participants, patients, pediatric, tocilizumab, type 1 diabetes
Author NameAffiliation
Carla J GreenbaumCenter for Interventional Immunology and Diabetes Program, Benaroya Research Institute
Elisavet Serti
Steven M WilliChildren's Hospital of Philadelphia, University of Pennsylvania
Kevan C HeroldYale University
Henry RodriguezUniversity of South Florida
Henry RodriguezUniversity of South Florida
Karen CerosalettiCenter for Interventional Immunology and Diabetes Program, Benaroya Research Institute
Sarah Alice LongCenter for Interventional Immunology and Diabetes Program, Benaroya Research Institute
Jane H BucknerCenter for Interventional Immunology and Diabetes Program, Benaroya Research Institute
  • 1 - 9

Datasets

Release 1.2